Big Pharma puts $250M towards disease collaboration

Share this article:

Big Pharma is pooling its resources and pitching in a combined $230 million for research efforts to identify biomarkers for diseases including Alzheimer's, type 2 diabetes and rheumatoid arthritis. The project, named the Accelerating Medicines Partnership, is corralled by the National Institutes of Health (NIH) and was two years in the making.

The research collaboration is expected to span between three and five years, and a key component of the effort is that the roster of drug makers—which includes AbbVie, Biogen Idec, GlaxoSmithKline, Merck and Takeda—is that they will share their results with the community at large, a strategy The Wall Street Journal notes is in line with an open-source approach that is used in other fields, but is generally anathema to a field in which healthful discoveries are valued for their scientific potential as well as their profit potential.

Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Business Briefs

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Business Briefs

Monday Moves: September 15

Hires and promotions for manufacturers, regulatory and agencies

Kantar acquires Evidências, expands Brazilian presence

The company's acquisition signals the growing importance of understanding the Brazilian healthcare market and evidence-based healthcare management services.

Study says statins not enough for diabetic hearts

Researchers using an experimental test have discovered that the 50% of surveyed diabetics may also have undetected heart muscle damage.